Search

everythinglearnresearchcommunity

for

Search:↓

Insufficient androgen action in male fetuses can cause genital development issues due to genetic mutations or environmental chemicals.

5α-reductase-2 deficiency causes ambiguous genitalia at birth and affects male sexual development, but individuals often develop male characteristics at puberty.

More hair loss leads to higher risk of psychosexual disorders, especially in women.

Men over 50 may experience hormone decline causing various symptoms, and proper management is crucial.

Ovulation disorders are a major cause of infertility and menstrual problems in women.

Male infertility and genitourinary birth defects are often linked to genetic issues.

Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.

Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.

5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.

Hormone imbalances from the pituitary, thyroid, and adrenal glands can cause infertility, but treating these disorders can improve fertility.

Young men's erectile dysfunction is linked to mental health issues and risky behaviors promoted by online communities, highlighting the need for better mental health support and healthy masculinity standards.

Excessive pre-ejaculation can be treated with certain medications.

Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.

Men may experience long-term sexual dysfunction after stopping Finasteride.

5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.

Certain medications, especially Paroxetine, Tamsulosin, and Finasteride, are linked to ejaculatory disorders.

Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.

The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.

Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.

The conclusion is that it's currently unclear if certain rare medical conditions are caused by specific factors due to mostly observational data.

Hair loss, prostate size, and urinary issues are related due to androgen effects.

Odds Ratios can be misleading; it's better to also present risk and Relative Risks for clarity.

Men with androgenetic alopecia may have more sexual dysfunctions.

Testosterone increases fluid secretion and aquaporin expression in the vas deferens, which is important for male fertility.

Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.

The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

BPH treatments can cause sexual side effects affecting quality of life.

Older men have different fertility histories and factors affecting fertility, suggesting they may benefit from earlier fertility evaluations.